SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced the issuance of U.S. Patent No.
9,833,177 titled "Insulin Pump Based Expert System." This
patent is part of the portfolio of intellectual property acquired by the
Company from Smiths Medical ASD, Inc. in 2013. It refers to a pump
system that suspends, among other operations, the delivery of insulin if
a user's sensor glucose data reaches or falls below an acceptable level,
alerts the user and recommends that the user initiate a blood glucose
measurement.
"This important patent directly relates to reducing patient risk for
hypoglycemia, which is the most valued aspect of automated insulin
delivery in our market research," said Kim Blickenstaff, President and
Chief Executive Officer of Tandem Diabetes Care. "There is increasing
industry focus on automating insulin delivery and the benefits it may
provide people with diabetes, and we believe this new patent
substantially strengthens Tandem's already robust portfolio of
intellectual property in support of these efforts."
U.S. Patent No. 9,833,177 is scheduled to expire in December
2028. The Company has a related U.S. continuation application on file.
Tandem Diabetes Care now has 56 issued U.S. patents and 52 pending U.S.
patent applications. In addition, the Company has, and is seeking,
patent protection for proprietary technologies in other countries
throughout the world.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, and the t:flex® Insulin Pump, the first pump
designed for people with greater insulin requirements. The t:slim X2 is
the only insulin pump available with Dexcom G5® Mobile continuous
glucose monitoring (CGM) integration. Tandem is based in San Diego,
California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on
Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2
is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are
registered trademarks of Dexcom, Inc. All other trademarks are the
property of their respective owners.
Forward-Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things the scope and enforceability of the
company's intellectual property, including the expected expiration of
the 9,833,177 patent. Many factors could cause the company's actual
results, performance or achievements to be materially different from any
future results, performance or achievements that may be expressed or
implied by such forward-looking statements, including without
limitation, those listed under the heading "Risk Factors" in the
company's most recent Annual Report on Form 10-K, Quarterly Report on
Form 10-Q and other documents that Tandem files with the Securities and
Exchange Commission. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of
this release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005446/en/
Tandem Diabetes Care, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media
